ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
ANI Pharmaceuticals (ANIP) has announced its participation in the upcoming 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company's President and CEO, Nikhil Lalwani, will conduct a fireside chat during the event.
The presentation will be available through a live and archived webcast on the company's website www.anipharmaceuticals.com under the Investors section's Events and Presentations area. Interested parties can access the webcast replay for 60 days following the event.
ANI Pharmaceuticals (ANIP) ha annunciato la sua partecipazione alla prossima Conferenza Virtuale di Oftalmologia RBC Capital Markets 2025. Il Presidente e CEO dell'azienda, Nikhil Lalwani, condurrà una chiacchierata informale durante l'evento.
La presentazione sarà disponibile tramite una diretta e una registrazione archiviata sul sito web dell'azienda www.anipharmaceuticals.com nella sezione Eventi e Presentazioni per gli Investitori. Le parti interessate possono accedere alla registrazione della diretta per 60 giorni dopo l'evento.
ANI Pharmaceuticals (ANIP) ha anunciado su participación en la próxima Conferencia Virtual de Oftalmología de RBC Capital Markets 2025. El Presidente y CEO de la empresa, Nikhil Lalwani, llevará a cabo una charla informal durante el evento.
La presentación estará disponible a través de una transmisión en vivo y una grabación archivada en el sitio web de la empresa www.anipharmaceuticals.com en la sección de Eventos y Presentaciones para Inversores. Las partes interesadas pueden acceder a la repetición de la transmisión durante 60 días después del evento.
ANI Pharmaceuticals (ANIP)는 다가오는 2025 RBC Capital Markets 안과 가상 회의에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Nikhil Lalwani가 행사 중에 대화형 세션을 진행할 예정입니다.
발표는 회사 웹사이트 www.anipharmaceuticals.com의 투자자 섹션 이벤트 및 발표 영역에서 실시간 및 아카이브된 웹캐스트를 통해 제공됩니다. 관심 있는 분들은 행사 후 60일 동안 웹캐스트 재생을 이용할 수 있습니다.
ANI Pharmaceuticals (ANIP) a annoncé sa participation à la prochaine Conférence Virtuelle d'Ophthalmologie RBC Capital Markets 2025. Le Président et CEO de l'entreprise, Nikhil Lalwani, animera une discussion informelle lors de l'événement.
La présentation sera disponible via un webcast en direct et archivé sur le site web de l'entreprise www.anipharmaceuticals.com dans la section Événements et Présentations pour les Investisseurs. Les parties intéressées peuvent accéder à la rediffusion du webcast pendant 60 jours après l'événement.
ANI Pharmaceuticals (ANIP) hat seine Teilnahme an der bevorstehenden 2025 RBC Capital Markets Augenheilkunde Virtuelle Konferenz bekannt gegeben. Der Präsident und CEO des Unternehmens, Nikhil Lalwani, wird während der Veranstaltung ein informelles Gespräch führen.
Die Präsentation wird über einen Live- und archivierten Webcast auf der Unternehmenswebsite www.anipharmaceuticals.com im Bereich Veranstaltungen und Präsentationen für Investoren verfügbar sein. Interessierte Parteien können die Wiederholung des Webcasts für 60 Tage nach der Veranstaltung abrufen.
- None.
- None.
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows:
| Date: | Thursday, April 3, 2025 |
| Time: | 7:45am ET |
| Webcast: | Click here |
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: ANI Pharmaceuticals, Inc.
FAQ
When is ANI Pharmaceuticals (ANIP) presenting at the RBC Capital Markets Ophthalmology Conference 2025?
How long will ANIP's RBC Conference presentation webcast be available for replay?
Where can investors access ANIP's 2025 RBC Conference presentation webcast?
Who will represent ANIP at the 2025 RBC Ophthalmology Conference?
